Inclusion Criteria:

- Stage IB to IIIA non-small cell lung cancer completely resected within 4 to 8 weeks
of initiating treatment on study

- Performance Status ECOG 0 or 1

- Peripheral neuropathy: < grade 1

- Adequate blood cell counts

- Adequate liver and hepatic function

- Women of childbearing potential must have a negative pregnancy test.

- Men and women of childbearing potential must be willing to consent to using effective
contraception while on treatment and for at least 3 months thereafter

Exclusion Criteria:

- Patients with a history of severe hypersensitivity reaction to Docetaxel® or other
drugs formulated with polysorbate 80.

- Women who are breast-feeding.

- Coexistent second malignancy or history of prior malignancy within previous 5 years
(excluding basal or squamous cell carcinoma of the skin that has been treated
curatively)

- Uncontrolled cardiac disease or uncontrolled hypertension